Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

Next Previous
Search
Trial Profile

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Imlunestrant (Primary) ; Alpelisib; Anastrozole; Everolimus; Exemestane; Letrozole; Pertuzumab; Trastuzumab
  • Indications Advanced breast cancer; Endometrial cancer; HER2 negative breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; First in man
  • Acronyms EMBER
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 04 Jun 2024 Results (n=72) assessing safety and efficacy of Imlunestrant in combination with abemaciclib, in endometrioid endometrial cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 04 Jun 2024 Results (n=45) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 29 May 2024 Planned End Date changed from 31 Dec 2024 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top